What looked like a historic breakthrough last week is turning out to be the start of a long, messy process. Here’s the full picture — with the facts that actually hold up.
Acting Attorney General Todd Blanche has done it: qualifying state-licensed medical marijuana and FDA-approved cannabis products in the United States have officially been moved from Schedule I to Schedule III. For many in the industry, the announcement came as a surprise — after two years of stock swings, empty promises, and bureaucratic gridlock, few had still believed it would happen.
But anyone popping champagne hasn’t read far enough.
What the Final Order Actually Does
The rescheduling hits three levers simultaneously: it removes the Section 280E tax burden for qualifying medical cannabis operators, introduces DEA registration requirements for state-licensed businesses, and creates a federal framework without dismantling existing state systems.
Important nuance: adult-use/recreational cannabis, unlicensed operations, and bulk cannabis outside the qualified framework remain Schedule I. This is not a blanket rescheduling of “cannabis” — it is a targeted measure for state-licensed medical operators and FDA-approved products.
Analyst Pablo Zuanic of Zuanic & Associates describes the outcome as “better than expected” — primarily because of what some analysts describe as “Federal Cover,” a concept that may enable better banking access, stock custody, and a more tolerant stance from exchanges. These are plausible market consequences, but not yet guaranteed legal outcomes.
Sounds promising. And it is — for roughly 32% of the industry.
The 68% Problem
Here lies the real issue that the initial wave of reporting largely ignored. According to CRB Monitor, only 32% of active US cannabis licences are medical-only. The remaining 68%, covering operators in adult-use states, are entirely unchanged by the order.
For the large Multi-State Operators holding both medical and recreational licences in the same states, a critical question remains completely unresolved: how to separate medical from recreational revenues for 280E purposes. IRS guidance has not yet arrived, and law firm analyses — including Foley & Lardner — explicitly flag this as an open issue with significant compliance risk.
The Clock Is Already Ticking
Operators who want to benefit from the relief have little time to waste. Only those who register with the DEA within 60 days of publication in the Federal Register — a window closing around June 22 — qualify for expedited review and may continue operating under their state licences while the federal application is pending.
The DEA has committed to processing early applications within six months. According to CRB Monitor analyst Paul Cheveriat, there are currently 18,444 active medical cannabis licences across the US — processing all of them within six months would be, as he puts it, “a major feat.”
The Compliance Trap Nobody Is Talking About
Compliance expert Deb Tharp has identified a structural risk that has so far flown under the radar. By validating state medical cannabis certifications at the federal level, the order simultaneously brings them under federal jurisdiction — and with that comes the “corresponding responsibility” doctrine, the same enforcement mechanism the DEA used to dismantle telehealth platforms in the ADHD medication space.
Under Schedule III, a cannabis sale only enjoys federal protection if it serves a “legitimate medical purpose.” Compliance experts warn that the DEA could connect federal registrant records, state seed-to-sale systems, and certification records to create exactly the kind of audit infrastructure the agency has previously used to identify and prosecute what it considers “pill mills.” This is a risk analysis, not a confirmed DEA policy — but one the industry should take seriously.
“The ‘Wild West’ of medical recommendations is over. The federal sheriff is in town — and he’s using your own data to track you.” — Deb Tharp (compliance analysis)
For dispensaries with high-volume telehealth relationships and practitioners issuing certifications at scale, the coming months may well be a compliance sprint rather than a victory lap.
How the Markets Will Reprice Cannabis
Investor sentiment was at a notable low before the announcement. According to ATB Cormark’s Spring 2026 Cannabis Investor Sentiment Survey (conducted April 13–21), investors had assigned only a 55% probability to rescheduling within twelve months — the second-lowest figure recorded across six surveys since 2023. Just 17.6% of respondents had increased their net exposure to MSOs in the previous six months, while 35.3% had decreased it.
ATB’s modelling — based on full rescheduling scenarios — suggests potential upside averaging 240% across the major MSOs, with Ascend and Verano showing the most dramatic potential moves. The MSOS ETF closed at $5.11, while 46.2% of investors expected $10 or above upon full rescheduling. What has been delivered is partial, and the market is now recalculating.
Key structural effects analysts expect:
- Balance sheets should reset — lower effective tax rates, improved free cash flow, and more manageable debt servicing for qualifying medical operators.
- Cost of capital may fall — lower regulatory risk and greater institutional comfort could reopen capital markets for operators previously locked out.
- Uplisting becomes a realistic conversation — DEA registration plus federal recognition reduces legal ambiguity and may soften exchange resistance.
- M&A momentum will likely build — stronger balance sheets enable acquisitions and scale becomes more important than ever.
Phase 2: What June 29 Can Actually Deliver
A hearing has been set for June 29 to discuss broader rescheduling of marijuana from Schedule I to Schedule III — expected to explore expansion toward the adult-use market. That sounds logical, but it is legally far more complicated.
The Single Convention on Narcotic Drugs, which provided the treaty pathway used for Phase 1, explicitly limits cannabis to medical and scientific purposes. Extending full rescheduling to recreational cannabis would require the complete administrative rulemaking process — with all the litigation exposure that entails. A final rule is possible by late 2026 at the earliest; legal challenges could push that horizon significantly further.
And challenges are coming. According to Foley Hoag’s Jeff Schultz, more than 20 Republican senators and 26 House Republicans have formally urged the administration to abandon rescheduling. Smart Approaches to Marijuana (SAM) has reportedly retained former Attorney General Bill Barr to litigate against any final rescheduling action.
What This Means for US Companies Eyeing Germany
Here is where this story gets particularly relevant for international operators — and particularly nuanced.
US rescheduling does not create an export pathway to Germany. American cannabis companies still cannot legally export cannabis products to the EU. But the rescheduling fundamentally changes the strategic calculus for US operators considering Germany as their first international market.
Capital unlocked = international expansion funded.
The 280E relief, improved balance sheets, and potentially declining cost of capital mean that serious MSOs may finally have the financial firepower to consider genuine international expansion. Germany is the obvious first destination. According to Prohibition Partners, Germany’s medical cannabis market surpassed EUR 670 million in 2025, running almost entirely on imports — with domestic production estimated at around 1–2% of total demand. The import gap is real and substantial.
The German opportunity is real — but the barriers are structural.
The German import market demands EU-GMP certification at the manufacturing level and GACP compliance at the cultivation level — non-negotiable requirements for accessing pharmacy channels. Certification is a lengthy process, commonly taking well over a year depending on the operator’s readiness. No amount of US federal rescheduling changes that timeline.
The acquisition route is the fastest path.
For US operators flush with rescheduling-driven capital, acquiring into an existing EU-GMP-certified European operation is considerably faster than building from scratch. North American companies that have already moved in this direction serve as an early proof of concept — the strategic logic is clear, even if execution is complex.
Germany’s regulatory wind is shifting — read it carefully.
Just as the US opens up, Germany is tightening. The German Federal Cabinet approved a draft amendment to the MedCanG in October 2025, proposing to require in-person consultations before first cannabis prescriptions. As of early 2026, this legislative process was still ongoing following a first Bundestag reading in December 2025. The draft has not yet passed into law, but the direction is clear: the telehealth-driven prescription model that fuelled Germany’s rapid patient growth is under regulatory pressure.
The parallel with the US is striking. The DEA’s “corresponding responsibility” risk for telehealth-heavy operators post-rescheduling mirrors almost exactly what the German health ministry is signalling domestically. US operators with telemedicine-heavy models need to read both trends together.
The scale of the prize.
According to market estimates cited by GrowerIQ, Germany’s medical cannabis patient base sits at around 900,000 — roughly 1.1% of the total population of 84 million. By any comparable market standard, penetration remains very low. The headroom for growth is significant, even as the regulatory environment matures.
The Bottom Line
US rescheduling is real, durable, and meaningful. For qualifying medical operators, it opens concrete doors: lower tax burden, better balance sheets, more capital market access, and M&A momentum.
But 68% of the US industry is still waiting. Compliance risks are more real than the initial euphoria suggested. Legal battles are just beginning. The IRS still owes the industry a lot of answers. And many of the optimistic market projections were built on scenarios of full rescheduling — not the partial order that was actually delivered.
For US operators looking toward Germany: rescheduling may give you the capital. Germany has the market. The bridge between the two requires EU-GMP certification, local partnerships, deep regulatory fluency — and the understanding that both markets are entering a phase of compliance maturity simultaneously.
The fight for full US rescheduling has just begun. And the race for the German market is already well underway.
Want to understand how the German market actually works? This week, Cannabis-Startups.com is hosting a DEEP-DIVE with Judith Heimbürger (gunnercooke) — one of Germany’s leading cannabis lawyers. 20 minutes, no fluff, straight answers.
